Press Release

AB-Therapeutics to participate at the annual meeting of the American Association of Cancer Research (AACR) in Chicago (USA)

During the congress the company will present the first data with the compound ABTL0812, on the mechanism of action and preclinical efficacy in experimental models of lung and pancreas.
The work presented has been selected by the evaluation committee of the AACR.

March 12, 2012

AB-Therapeutics, SL, pharmaceutical biotechnology company with a product in clinical phase planned for the third quarter of 2012, announced today that Jose Alfon, PhD, Director of Development, will participate in the Annual Meeting of the American Association of Cancer Research (AACR ) in Chicago from March 31 to April 4. Dr. Alfon will present the first data on the mechanism of action and preclinical efficacy in experimental models of lung and pancreas with the  compound ABTL0812. The work presented has been selected by the evaluation committee of the AACR.

ABTL0812 presents significant advantages over conventional chemotherapy: very low toxicity, oral administration, and most importantly, high efficacy. The product affects two cellular processes related to cell division and thus the proliferation of cancer cells: a) synthesis of DNA through inhibition of the expression of the dihydrofolate reductase (DHFR)
gene, and b) inhibiting mTOR pathway that is involved in protein synthesis. By blocking these two key cellular functions, tumor cells are killed by a mechanism called autophagy, in which cells digest themselves.

About AB-Therapeutics, SL

AB-
Therapeutics, SL is a research and development biopharmaceutical company founded in 2009 with headquarters in Bellaterra (Barcelona), Catalonia, Spain, located at the campus of the Autonomous University of Barcelona and with facilities planned in Boston in the US for 2012 .
AB-Therapeutics, SL aims to develop safer human therapies, based on the modulation of the activity of cell-membranes to treat various cancers, especially those with high medical needs due to its high mortality. The firm has a molecule, ABTL0812, in regulatory preclinical development, Phase I clinical trials (First in Man) is planned for the third quarter of 2012. A second drug candidate, ABTL1014 will begin preclinical development during the last quarter of 2012.
 

Contact:

Press:
Nuria Peláez
Tel +34 902 903 844
media.relations@ab-therapeutics.com
 
www.ab-therapeutics.com

Investors:
Carles Domenech, PhD
Tel +34 935 868 977
contact@ab-therapeutics.com
www.ab-therapeutics.com

LATEST NEWS

11.03.2024

Press Release

AbilityPharma Announces € 7 Million Financing Round to Advance Development of its Clinical Phase 2b Autophagy Inducer ABTL0812 in Metastatic Pancreatic Cancer + info
02.06.2023

Press Release

Ability Pharmaceuticals announces the presentation of the phase 2a results of ABTL0812 as first-line therapy in patients with lung cancer at the ASCO 2023 Annual Meeting in Chicago + info
14.12.2022

Press Release

AbilityPharma Achieves the 30% of the Estimated Recruitment for their Phase 2b Clinical Trial with ABTL0812 + FOLFIRINOX as a First-Line Therapy Treatment in Advanced Pancreatic Cancer + info
21.11.2022

Press Release

AbilityPharma Obtains 1,5M € of Non-Dilutive Funding from Next Generation EU Funds to Further Study the Anticancer Immunomodulatory Effects of ABTL0812 + info
10.11.2022

Press Release

AbilityPharma will attend LSX investical showcase in London to meet with key investors and venture capital firms + info
02.11.2022

Press Release

ABTL0812 shows potential against glioblastoma brain tumors + info
07.10.2022

Press Release

AbilityPharma Secures 2,2M € of Non-Dilutive Funding from the Ministry of Science & Innovation of the Government of Spain to Accelerate the Clinical Development and Regulatory Path of ABTL0812 + info
07.09.2022

Press Release

Carles Domènech, Executive Chairman & CEO of AbilityPharma, Will Attend ESMO Congress in Paris for a Meeting with some of the most Relevant Key Opinion Leaders (KOLs) in the Treatment of Pancreatic Cancer + info
29.06.2022

Press Release

AbilityPharma Will Attend ESMO World Congress on Gastrointestinal Cancer 2022 in Barcelona + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
NEORG